Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arginine glutamate is a pharmaceutical combination consisting of the amino acids L-arginine and L-glutamic acid, typically administered as a salt. It is primarily indicated for the treatment of hyperammonemia and hepatic encephalopathy associated with chronic liver diseases such as cirrhosis. The drug works through a dual mechanism to detoxify ammonia: L-arginine serves as a critical intermediate in the urea cycle, promoting the conversion of toxic ammonia into urea in the liver, while L-glutamic acid reacts with ammonia to form glutamine via the action of glutamine synthetase, providing an alternative pathway for ammonia removal in the brain and peripheral tissues. Furen Pharmaceutical Group is a prominent developer and manufacturer of this combination in China, where it is widely used in clinical practice for liver-related metabolic disturbances.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arginine glutamate.